This Month
‘Thankful’ Scolyer surprised to be alive despite brain cancer’s return
But the former Australian of the Year says “I feel devastated and upset” after prolonging his life with a revolutionary treatment.
September 2022
Cancer biotech hunts $50m as it kicks off phase-two trial
Aucentra Therapeutics has doubled the size of its capital raise amid interest from investors in its CDK4/6 inhibitor drug.
August 2021
Telix Pharma is on the cusp of first US FDA approval
The nuclear medicine company is not only going after the huge US market, it has the equivalent documentations with 17 other countries’ regulators.
July 2021
Australia’s richest families back brain mapping software company
Omniscient Neurotechnology has raised $40 million in series B financing from wealthy individuals, including Will Vicars and Gina Rinehart.
May 2021
Imugene pens global patent licensing deal with LA-based research centre
ASX-listed immuno-oncology company has entered a deal with City of Hope for a novel cancer therapy targeting solid tumours that would otherwise be tough to treat.
September 2020
Biotech Kazia taps Bells for entitlement offer
Sydney-based biotech outfit Kazia Therapeutics is hunting a $25.2 million cash injection, to fund its participation in an international bran cancer study.
July 2020
Scientists warn of potential wave of COVID-linked brain damage
Doctors say millions could be affected by brain damage and neurological complications after contracting COVID-19.